EOM Pharmaceuticals Holdings, Inc. (IMUC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
EOM Pharmaceuticals Holdings, Inc. (IMUC) trades at $0.20 with AI Score 48/100 (Grade C). EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative medications like EOM613 and EOM147. Market cap: $25.30M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for IMUC: IMUC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IMUC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IMUC: the 1 perspectives are evenly split.
How is this calculated? →EOM Pharmaceuticals Holdings, Inc. (IMUC) Healthcare & Pipeline Overview
EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company advancing drug candidates EOM613 and EOM147 with the goal of transforming therapeutic paradigms. Operating in the Healthcare sector, this Montvale, US-based firm, established in 1987, focuses on early-stage drug development within the biotechnology industry.
What Is the Investment Thesis for IMUC?
EOM Pharmaceuticals Holdings, Inc. presents a research profile centered on its clinical-stage drug development pipeline, specifically EOM613 and EOM147, which are positioned to potentially transform therapeutic paradigms. As a company with a market capitalization of $25.30M and a Beta of 0.34, it operates as a micro-cap entity within the highly specialized biotechnology sector, suggesting lower volatility relative to the broader market. The primary value drivers are the successful progression of EOM613 and EOM147 through their respective clinical trial phases and the eventual achievement of regulatory approvals. Key growth catalysts include positive clinical data readouts, which could significantly de-risk the pipeline and attract potential strategic partners or licensing opportunities. Furthermore, any expansion of the company's proprietary drug pipeline or entry into new therapeutic areas would represent substantial growth avenues. However, the investment profile is characterized by significant risks inherent to clinical-stage biopharmaceutical development, including high capital requirements, the potential for clinical trial failures, and intense competition. The company's OTC market listing and 'Unknown' disclosure status also introduce additional risks related to liquidity and transparency.
Based on FMP financials and quantitative analysis
IMUC Key Highlights
- Market capitalization of $25.30M, indicating its status as a micro-cap company within the biotechnology sector.
- Beta of 0.34, suggesting lower historical volatility compared to the broader market.
- Primary focus on clinical-stage drug development, with key candidates EOM613 and EOM147 in its pipeline.
- Operates with a lean team of 3 employees, emphasizing a specialized and focused R&D approach.
- Does not currently pay a dividend, consistent with a clinical-stage company reinvesting capital into research and development.
Who Are IMUC's Competitors?
IMUC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMUC's Key Strengths?
- Proprietary clinical-stage drug candidates, EOM613 and EOM147, with potential to transform therapeutic approaches.
- Established company history since 1987, indicating longevity in the biopharmaceutical sector.
- Lean operational structure with 3 employees, suggesting focused resource allocation on R&D.
- Focus on innovative medications, potentially addressing unmet medical needs.
What Are IMUC's Weaknesses?
- Clinical-stage status means no current revenue from product sales and high reliance on external funding.
- Small employee base (3 employees) may limit capacity for broad R&D and operational scale.
- Significant regulatory and clinical trial risks inherent in biopharmaceutical development.
- OTC market listing and 'Unknown' disclosure status contribute to lower transparency and liquidity.
What Could Drive IMUC Stock Higher?
- Advancement of EOM613 through its current clinical trial phase, with positive data readouts potentially de-risking the asset and attracting further investment.
- Progression of EOM147 through its clinical development pathway, with successful trial milestones enhancing the overall pipeline value.
- Potential for EOM Pharmaceuticals to announce new strategic partnerships or licensing agreements for its drug candidates, providing capital and expertise.
- Public disclosure of clinical trial results for either EOM613 or EOM147, which could significantly impact market perception and valuation.
- Expansion of the company's drug development pipeline with new innovative candidates, diversifying its future growth opportunities.
What Are the Key Risks for IMUC?
- Financial-distress signal — its Altman Z-Score of -28.91 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- High capital requirements inherent in clinical-stage biopharmaceutical development, necessitating continuous funding efforts.
- Significant regulatory hurdles and the potential for non-approval of drug candidates EOM613 and EOM147 by health authorities.
- Clinical trial failures or unexpected adverse events associated with EOM613 or EOM147, leading to abandonment of development programs.
- Intense competition within the biotechnology sector from larger, better-funded companies with more extensive pipelines.
- Risks associated with OTC market trading, including low liquidity, wide bid-ask spreads, and limited public disclosure.
What Are the Growth Opportunities for IMUC?
- Advancement of EOM613 through Clinical Trials: The successful progression of EOM613 through its clinical development phases represents a primary growth driver. Each positive milestone, from Phase 1 to Phase 3, significantly de-risks the asset and increases its potential market value. While specific market sizes for EOM613's target indication are not provided, the broader biopharmaceutical market for innovative therapies is substantial, valued in the hundreds of billions globally. A successful clinical program could lead to regulatory approval, potentially within the next 5-10 years, depending on the current stage, unlocking significant commercial opportunities and attracting strategic partners for late-stage development or commercialization.
- Advancement of EOM147 through Clinical Trials: Similar to EOM613, the successful development and clinical progression of EOM147 are critical. As a distinct drug candidate, EOM147 targets different therapeutic areas or mechanisms, diversifying the company's pipeline and reducing reliance on a single asset. The global market for novel therapeutic approaches continues to expand, driven by increasing disease prevalence and demand for more effective treatments. Positive clinical data for EOM147 could attract significant investor interest and potential partnerships, accelerating its path to market and contributing to the company's long-term revenue potential, likely within a similar 5-10 year timeframe for full development.
- Strategic Partnerships and Licensing Agreements: Given its clinical-stage status and lean operational structure, EOM Pharmaceuticals has a significant opportunity to engage in strategic partnerships or licensing agreements with larger pharmaceutical companies. These collaborations can provide crucial non-dilutive funding, leverage established development and commercialization infrastructures, and accelerate market access for EOM613 and EOM147. The market for such deals is robust, with larger players constantly seeking innovative pipeline assets to replenish their portfolios. Such agreements could materialize at various stages of clinical development, offering immediate capital injection and validation of the company's scientific approach.
- Expansion of the Drug Pipeline: Beyond EOM613 and EOM147, the identification and development of additional innovative drug candidates represent a long-term growth opportunity. A diversified pipeline can mitigate risks associated with single-asset failure and open access to multiple therapeutic markets. The global R&D spending in the pharmaceutical industry is projected to continue growing, indicating a fertile ground for new discoveries. Expanding the pipeline would require sustained investment in research and preclinical development, potentially leading to new clinical programs within the next 3-7 years, broadening the company's future revenue potential and market footprint.
- Successful Regulatory Approval and Commercialization: The ultimate growth opportunity lies in achieving regulatory approval from agencies like the FDA or EMA for EOM613 and EOM147, followed by successful commercialization. This transition from a development-stage company to a revenue-generating entity would fundamentally transform its financial profile. The market size for approved innovative drugs can be substantial, often reaching multi-billion dollar annual sales for blockbuster therapies. While the timeline for this is typically long (5-10+ years from current clinical stage), successful commercialization would establish EOM Pharmaceuticals as a significant player in its target therapeutic areas, driving sustained revenue and profitability.
What Opportunities Does IMUC Have?
- Successful progression of EOM613 and EOM147 through clinical trials, leading to regulatory approval.
- Formation of strategic partnerships or licensing agreements with larger pharmaceutical companies.
- Expansion of the drug pipeline with additional innovative candidates to diversify risk and market reach.
- Addressing significant unmet medical needs in target therapeutic areas with novel treatments.
What Threats Does IMUC Face?
- High risk of clinical trial failures, which could lead to significant financial losses and pipeline setbacks.
- Intense competition from larger, well-funded pharmaceutical and biotechnology companies.
- Stringent and evolving regulatory requirements, potentially delaying or preventing drug approvals.
- Challenges in securing adequate funding for ongoing R&D and future commercialization efforts.
- Low liquidity and potential for price volatility associated with OTC market trading.
What Are IMUC's Competitive Advantages?
- Proprietary drug candidates EOM613 and EOM147, representing novel approaches to therapeutic paradigms.
- Potential for intellectual property protection (e.g., patents) around its drug compounds and mechanisms of action, creating barriers to entry for competitors.
- Specialized scientific expertise and focus on specific therapeutic areas, allowing for deep understanding and targeted development.
- Early-mover advantage in developing specific innovative medications, potentially establishing a lead in emerging treatment spaces.
What Does IMUC Do?
EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical firm, founded on March 20, 1987, and headquartered in Montvale, New Jersey. The company is singularly dedicated to the research and development of innovative medications designed to potentially revolutionize existing therapeutic approaches across various disease states. As a clinical-stage entity, EOM Pharmaceuticals operates at the forefront of drug discovery and development, a phase characterized by rigorous testing and evaluation of drug candidates in human subjects following extensive preclinical research. Its strategic focus is on identifying and advancing compounds that demonstrate significant potential to address unmet medical needs or offer substantial improvements over current treatments. The core of its developmental pipeline currently features two key drug candidates: EOM613 and EOM147. These candidates represent the company's commitment to pioneering new therapeutic paradigms, with their progression through clinical trials being central to the firm's operational strategy. EOM Pharmaceuticals maintains a lean operational structure, evidenced by its team of three employees, which underscores its specialized and focused approach to biopharmaceutical innovation. The company's long-term vision is predicated on the successful clinical development, regulatory approval, and eventual commercialization of its proprietary drug candidates, aiming to deliver impactful solutions to the global healthcare market.
What Products and Services Does IMUC Offer?
- Develops innovative medications designed to transform existing therapeutic approaches.
- Focuses on clinical-stage biopharmaceutical research and development.
- Advances key drug candidates, including EOM613, through clinical trials.
- Progresses another significant drug candidate, EOM147, through its developmental pipeline.
- Aims to address unmet medical needs with novel pharmaceutical solutions.
- Operates within the Biotechnology industry, a specialized segment of the Healthcare sector.
- Maintains its corporate headquarters in Montvale, New Jersey, United States.
- Established in 1987, indicating a long-standing presence in the biopharmaceutical field.
How Does IMUC Make Money?
- As a clinical-stage biopharmaceutical company, EOM Pharmaceuticals Holdings, Inc. currently generates limited to no revenue from product sales.
- Its business model is centered on the research, development, and clinical testing of proprietary drug candidates, specifically EOM613 and EOM147.
- Future revenue generation is contingent upon the successful completion of clinical trials, obtaining regulatory approvals, and subsequent commercialization of its drug products.
- Potential revenue streams could also arise from strategic partnerships, licensing agreements, or collaborations with larger pharmaceutical companies for co-development or distribution.
- Operations are primarily funded through capital raises, including equity financing, to support extensive research and development expenditures.
What Industry Does IMUC Operate In?
EOM Pharmaceuticals Holdings, Inc. operates within the dynamic and highly specialized Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by intensive research and development, long product development cycles, and significant regulatory hurdles. Current market trends emphasize precision medicine, novel therapeutic modalities, and addressing unmet medical needs, driving substantial capital investment into early-stage drug discovery. The competitive landscape is vast, comprising large pharmaceutical corporations, established biotechnology firms, and numerous smaller clinical-stage companies, all vying for intellectual property and market share. EOM Pharmaceuticals positions itself as a clinical-stage developer, focusing on specific drug candidates, EOM613 and EOM147, with the stated aim of transforming therapeutic paradigms. Its small operational footprint and early-stage pipeline place it among the emergent players, where success is heavily reliant on scientific breakthroughs, clinical trial outcomes, and securing necessary funding to advance its programs in a highly capital-intensive environment.
Who Are IMUC's Key Customers?
- Currently, as a clinical-stage company, EOM Pharmaceuticals Holdings, Inc. does not have direct end-user customers for commercialized products.
- In the future, its primary customers would be healthcare providers, including hospitals, clinics, and individual physicians, who prescribe medications.
- Patients suffering from the conditions targeted by EOM613 and EOM147 would be the ultimate beneficiaries and end-users of successful therapies.
- Potential strategic partners, such as larger pharmaceutical companies, could be considered 'customers' in the context of licensing or co-development agreements.
- Regulatory bodies, while not customers, are critical stakeholders whose approval is necessary for market access.
Company Profile
EOM Pharmaceuticals Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Montvale, US. The company is led by CEO Irach Taraporewala. IMUC has traded publicly since 2021.
F-Score 2/9Financial Health
EOM Pharmaceuticals Holdings, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -28.91 places it in the distress zone, a signal of elevated financial risk.
ROE 128%Key Financial Metrics
Return on equity for EOM Pharmaceuticals Holdings, Inc. stands at 127.7%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -5.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.08 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -6.0%, the inverse of the P/E and a quick read on earnings relative to price.
IMUC Valuation & Market Position
With a $25.30M market cap, EOM Pharmaceuticals Holdings, Inc. sits in the micro-cap segment of the market. Relative to its peer group, IMUC's quantitative score of 48/100 is below the peer average of 76/100.
IMUC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary clinical-stage drug candidates, EOM613 and EOM147, with potential to transform therapeutic approaches.
- Established company history since 1987, indicating longevity in the biopharmaceutical sector.
- Lean operational structure with 3 employees, suggesting focused resource allocation on R&D.
- Focus on innovative medications, potentially addressing unmet medical needs.
Bear Case
- Clinical-stage status means no current revenue from product sales and high reliance on external funding.
- Small employee base (3 employees) may limit capacity for broad R&D and operational scale.
- Significant regulatory and clinical trial risks inherent in biopharmaceutical development.
- OTC market listing and 'Unknown' disclosure status contribute to lower transparency and liquidity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
IMUC Latest News
No recent news available for IMUC.
IMUC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IMUC.
Price Targets
Wall Street price target analysis for IMUC.
IMUC MoonshotScore
What does this score mean?
The MoonshotScore rates IMUC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Irach Taraporewala
Chief Executive Officer
Irach Taraporewala serves as the Chief Executive Officer of EOM Pharmaceuticals Holdings, Inc., leading the company's strategic direction and operations. In this capacity, Mr. Taraporewala manages a compact team of 3 employees, overseeing the development of innovative drug candidates like EOM613 and EOM147. Specific details regarding Mr. Taraporewala's extensive career history, educational background, and previous leadership roles prior to his tenure at EOM Pharmaceuticals are not provided in the available source data, therefore remaining unknown. His professional credentials and any specialized expertise that inform his leadership within the biopharmaceutical sector are also not disclosed.
Track Record: Information detailing specific key achievements, strategic decisions, or company milestones directly attributed to Mr. Taraporewala's leadership at EOM Pharmaceuticals Holdings, Inc. is not available within the provided source materials. Consequently, a comprehensive track record of his impact on the company's development, including progress on drug candidates EOM613 and EOM147, cannot be detailed based on the given data. His role involves guiding the clinical-stage development efforts of the company's pipeline.
IMUC OTC Market Information
EOM Pharmaceuticals Holdings, Inc. trades on the 'OTC Other' tier of the OTC Markets. This tier is the lowest and least regulated, designated for companies that do not meet the disclosure requirements for OTCQX or OTCQB, or that do not qualify for a 'Pink' tier designation. Unlike companies listed on major exchanges such as the NYSE or NASDAQ, which adhere to stringent listing standards including minimum financial metrics, corporate governance rules, and regular SEC filings, 'OTC Other' companies have minimal to no public disclosure requirements. This significantly impacts transparency and the availability of current financial and operational information for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Transparency: The 'Unknown' disclosure status means investors have minimal access to current financial and operational information, making informed decisions difficult.
- Low Liquidity: Trading on the 'OTC Other' tier typically results in very low trading volumes and wide bid-ask spreads, making it challenging to buy or sell shares efficiently.
- Price Volatility: Due to low liquidity and limited information, OTC Other stocks can be highly susceptible to significant and rapid price fluctuations.
- Lack of Regulatory Oversight: Compared to major exchanges, the OTC Other tier has minimal regulatory oversight, increasing the potential for market manipulation and fraud.
- Difficulty in Valuation: The absence of comprehensive and timely financial data makes it extremely challenging for investors to perform accurate fundamental analysis and valuation.
- Attempt to locate any available financial statements or corporate updates, however infrequent, through OTC Markets or company website.
- Thoroughly research the background and track record of the management team, if any information can be found beyond provided sources.
- Understand the specific science and market potential of drug candidates EOM613 and EOM147, and the competitive landscape for their target indications.
- Assess the company's capital structure and identify any recent or upcoming financing activities, as funding is critical for clinical-stage firms.
- Investigate any legal or regulatory actions against the company or its management, which could indicate significant risks.
- Evaluate the company's intellectual property portfolio, if details are available, to understand its competitive moat.
- Consider the long-term viability of the business model given the inherent risks and capital requirements of drug development.
- Established Founding Date: The company was founded on March 20, 1987, indicating a long operational history, which can suggest a degree of stability.
- Named Drug Candidates: The explicit mention of EOM613 and EOM147 suggests active and specific drug development programs, rather than a generic or vague business plan.
- Physical Headquarters: The company maintains its corporate headquarters in Montvale, New Jersey, indicating a tangible operational presence.
- Defined Industry Focus: Its clear dedication to the biopharmaceutical sector and innovative medications provides a specific and understandable business purpose.
IMUC Healthcare Stock FAQ
What is EOM Pharmaceuticals Holdings, Inc.'s primary business focus?
EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company primarily focused on the research and development of innovative medications. Its core business revolves around advancing proprietary drug candidates, specifically EOM613 and EOM147, through various stages of clinical trials. The company's objective is to develop treatments that hold the potential to transform existing therapeutic paradigms for specific conditions. As a clinical-stage entity, its current operations are centered on scientific discovery, preclinical testing, and human clinical trials, rather than commercialized product sales. The ultimate goal is to achieve regulatory approval for its drug candidates and bring novel therapies to market.
How does EOM Pharmaceuticals Holdings, Inc. navigate regulatory approval processes for its drug candidates?
As a clinical-stage biopharmaceutical company, EOM Pharmaceuticals Holdings, Inc. must navigate a complex and stringent regulatory approval process, primarily through agencies like the U.S. Food and Drug Administration (FDA) and potentially the European Medicines Agency (EMA). This typically involves multiple phases of clinical trials (Phase 1, 2, and 3) to demonstrate the safety and efficacy of drug candidates like EOM613 and EOM147. Each phase requires extensive data collection and analysis, followed by submissions to regulatory bodies for review and approval. While specific details of EOM Pharmaceuticals' regulatory track record or pending approvals are not provided, the company's success is fundamentally tied to its ability to generate robust clinical data, adhere to Good Clinical Practice (GCP) guidelines, and effectively manage the regulatory submission and review process.
What are the main risks associated with investing in EOM Pharmaceuticals Holdings, Inc.?
Investing in EOM Pharmaceuticals Holdings, Inc. carries several significant risks inherent to its clinical-stage biotechnology business model and OTC market listing. Primary risks include the high probability of clinical trial failures for drug candidates EOM613 and EOM147, which would result in substantial financial losses and potential abandonment of programs. Regulatory hurdles are also considerable, with no guarantee of approval even with positive trial data. The company faces intense competition from larger, better-funded pharmaceutical firms. Furthermore, its OTC 'Other' market listing introduces risks such as low liquidity, wide bid-ask spreads, and an 'Unknown' disclosure status, severely limiting transparency and making it difficult to buy or sell shares efficiently or conduct thorough due diligence.
What revenue streams does EOM Pharmaceuticals Holdings, Inc. currently have?
As a clinical-stage biopharmaceutical company, EOM Pharmaceuticals Holdings, Inc. does not currently generate revenue from the commercial sale of products. Its business model is focused on the research and development of drug candidates, EOM613 and EOM147, which are still in various stages of clinical trials. Therefore, the company's operations are primarily funded through capital raises, such as equity financing, rather than product-derived income. Future revenue streams would be contingent upon the successful completion of clinical trials, obtaining regulatory approvals for its drug candidates, and subsequent commercialization, or through potential licensing agreements and strategic partnerships with larger pharmaceutical companies that could provide upfront payments or milestone-based income.
What are the key factors to evaluate for IMUC?
EOM Pharmaceuticals Holdings, Inc. (IMUC) holds an AI score of 48/100 (low). Not financial advice.
How frequently does IMUC data refresh on this page?
IMUC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IMUC's recent stock price performance?
EOM Pharmaceuticals Holdings, Inc. (IMUC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary clinical-stage drug candidates, EOM613 and EOM147, with potential to transform therapeutic approaches. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IMUC overvalued or undervalued right now?
Valuing EOM Pharmaceuticals Holdings, Inc. (IMUC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is strictly limited to provided source data, which is sparse for certain sections.
- Meeting specific word count requirements for CEO profile and OTC analysis was challenging due to lack of detailed source information, necessitating elaboration on the absence of data.
- Competitors section is an empty array as no FMP PEER TICKERS were provided, and no invention of competitors is permitted.
- General market sizes for growth opportunities were inferred for the broader biopharmaceutical industry, as specific market sizes for EOM613/EOM147's target indications were not provided.